Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:FMC
NYSE:FMCChemicals

A Look At FMC (FMC) Valuation As Governance Reforms Shift Shareholder Rights

Why FMC’s governance reforms matter for shareholders FMC (FMC) has drawn fresh attention after proposing governance changes ahead of its April 28, 2026 annual meeting, including removing supermajority voting and giving investors holding 25% the ability to call special meetings. For current and potential shareholders, these proposals focus attention on how much influence investors have over board decisions, future corporate actions, and the company’s overall approach to accountability and...
TASE:MLTH
TASE:MLTHIT

Malam Team Holdings Q4 EPS Loss Challenges Bullish Margin Narrative Despite Lower P E Versus Peers

Malam-Team Holdings (TASE:MLTH) has wrapped up FY 2025 with Q4 revenue of ₪1.1b and a basic EPS loss of ₪0.32, a sharp contrast to the prior year’s Q4 basic EPS of ₪2.16. Over recent quarters, the company has seen quarterly revenue move from ₪1.05b in Q4 2024 to ₪1.12b in Q3 2025 before landing at ₪1.1b in Q4 2025. Basic EPS shifted from ₪2.16 in Q4 2024 to positive peaks of ₪3.27 in Q3 2025 before slipping into the Q4 loss. For investors, the combination of higher revenue scale with a weak...
NasdaqGS:AMRX
NasdaqGS:AMRXPharmaceuticals

How Amneal’s Margin-Focused 2026 Outlook and 2025 Results Could Impact Amneal Pharmaceuticals (AMRX) Investors

In 2025, Amneal Pharmaceuticals reported past annual results showing revenue of US$3.02 billion, operating income of US$421 million, and net leverage of 3.5x, alongside issuing mixed 2026 guidance with modest revenue growth but faster adjusted EBITDA and EPS growth expectations. A key insight is that the company’s outlook emphasizes higher-margin growth supported by biosimilars and new product launches, even as overall revenue guidance remains relatively restrained. We’ll now examine how...
TSX:GUD
TSX:GUDPharmaceuticals

Knight Therapeutics Q4 Profit Tests Bullish Earnings Narrative After Yearlong Loss

Knight Therapeutics FY 2025 earnings snapshot Knight Therapeutics (TSX:GUD) has wrapped up FY 2025 with Q4 revenue of C$133.1 million and basic EPS of C$0.09, capping a year where the trailing twelve month figures show C$450.1 million in revenue and a basic EPS loss of C$0.05. Over recent quarters, revenue has moved from C$96.9 million in Q4 2024 to C$88.1 million in Q1 2025, C$107.4 million in Q2 2025, C$121.5 million in Q3 2025 and C$133.1 million in Q4 2025. Quarterly EPS has ranged...
OB:TEL
OB:TELTelecom

Telenor (OB:TEL) Valuation Check After New Safestate Group Partnership Announcement

The newly announced partnership between Telenor (OB:TEL) and Safestate Group puts fresh attention on how Telenor’s connectivity, business services, and infrastructure could support new commercial opportunities and reshape how investors view the stock. See our latest analysis for Telenor. At a share price of NOK168.4, Telenor has recently seen a 4.48% 1 month share price decline, yet its 90 day share price return of 17.84% and 3 year total shareholder return of 69.20% point to momentum that...
NYSE:OMC
NYSE:OMCMedia

Omnicom Interpublic Deal Reshapes Agencies With Synergies And Job Cuts

Omnicom Group (NYSE:OMC) has completed its $13b acquisition of Interpublic Group. The company plans a major restructuring that includes 4,000 job cuts. Omnicom will consolidate several agency brands as part of its post deal integration. For investors tracking NYSE:OMC, this deal creates one of the largest combined marketing services groups, with a share price of $75.84 as of the last close. The stock is up 11.6% over the past 30 days, while the 5 year return stands at 18.5%. The integration...
NasdaqGS:ZG
NasdaqGS:ZGReal Estate

Is It Time To Reassess Zillow Group (ZG) After A 31.6% Year To Date Decline?

Wondering whether Zillow Group at around US$44.89 is pricing in too much hope or not enough, this article focuses squarely on what the current share price implies about value. The stock has moved 10.0% over the past 7 days and 2.0% over the past 30 days. Yet year to date the return sits at a 31.6% decline, with a 35.2% decline over 1 year and a 65.8% decline over 5 years. Investors have been reacting to ongoing headlines around the US housing market, changing mortgage affordability and the...
TASE:SANO1
TASE:SANO1Household Products

Sano Bruno's Enterprises (TASE:SANO1) Margin Improvement Challenges Bearish Valuation Narratives

Sano Bruno's Enterprises (TASE:SANO1) has wrapped up FY 2025 with fourth quarter revenue of ₪531.1 million and basic EPS of ₪6.61, alongside trailing twelve month revenue of about ₪2.2 billion and EPS of ₪25.10. Over recent periods, the company has seen quarterly revenue move in a tight band between ₪531.1 million and ₪586.2 million, while quarterly EPS ranged from ₪5.01 to ₪7.24. This sets up a picture of earnings supported by a trailing net profit margin of 12.6% compared with 11.6% last...
NYSE:UBER
NYSE:UBERTransportation

Uber Rivian Robotaxi Deal Tests Uber’s Capital Light Story

Uber Technologies (NYSE:UBER) plans to invest up to $1.25b in Rivian Automotive to deploy fully autonomous electric robotaxis. The partnership is exclusive for this vehicle program, with up to 50,000 Rivian R2 robotaxis targeted to operate on Uber's platform by 2031. Initial deployment is planned for 2028, with a rollout across 25 cities in the U.S., Canada, and Europe. The deal marks Uber's return to owning and operating a large autonomous fleet after several years focused on an asset light...
SWX:SQN
SWX:SQNCapital Markets

Swissquote Group Holding (SWX:SQN) Margin Strength Reinforces Bullish Narratives In FY 2025 Results

Swissquote Group Holding (SWX:SQN) has put up a busy FY 2025 scorecard, with second half revenue of CHF 388.1 million and basic EPS of CHF 13.88 sitting alongside trailing twelve month revenue of CHF 760.8 million and EPS of CHF 24.49, underpinned by reported earnings growth of 24.6% over the last year. The company has seen revenue move from CHF 356.9 million in the second half of 2024 to CHF 372.7 million in the first half of 2025 and CHF 388.1 million in the second half of 2025, while net...
NYSEAM:UMAC
NYSEAM:UMACElectronic

Unusual Machines (UMAC) Is Down 16.0% After Launching Lantronix Defense-Focused Drone AI Partnership - What's Changed

In March 2026, Lantronix Inc. and Unusual Machines, Inc. announced a collaboration to co-develop next-generation autonomous drone components that combine Lantronix’s edge AI compute with Unusual Machines’ mission-critical flight control systems, aimed at U.S. defense, public safety, and commercial use cases under the US$1.10 billion Drone Dominance Program. The partnership’s modular, upgradeable architecture and focus on trusted domestic supply chains could make Unusual Machines a more...
NYSE:TIC
NYSE:TICProfessional Services

Is TIC’s Buyback and ESOP Plan Amid Losses Altering The Investment Case For TIC Solutions (TIC)?

TIC Solutions, Inc. has recently reported a fourth-quarter 2025 net loss of US$47.2 million and a full-year 2025 net loss of US$87.12 million, while also announcing a new CEO, Benjamin Heraud, a US$200 million share repurchase program, and fresh shelf registrations including an ESOP-related offering. The combination of deeper employee ownership via the ESOP-related share registration and a sizeable buyback plan highlights management’s commitment to capital returns and workforce alignment...
TSX:CFW
TSX:CFWEnergy Services

Calfrac Well Services (TSX:CFW) Margin Recovery Challenges Cautious Valuation Narratives

Calfrac Well Services (TSX:CFW) has capped FY 2025 with fourth quarter revenue of $292.2 million and basic EPS of $0.18, supported by trailing twelve month revenue of $1.39 billion and EPS of $0.47. Over recent reporting periods, revenue has ranged from $292.2 million to $402.3 million a quarter, while basic EPS has moved between $0.05 and $0.18 in 2025. This gives investors a clearer read on how the top line and per share earnings are tracking through the year. Taken together, the latest...
NYSE:ABT
NYSE:ABTMedical Equipment

Abbott Acquisition Of Exact Sciences Refocuses Growth On Cancer Diagnostics

Abbott Laboratories (NYSE:ABT) has announced an agreement to acquire Exact Sciences, expanding its presence in cancer diagnostics. The deal is aimed at strengthening Abbott’s diagnostics portfolio and integrating Exact Sciences’ cancer testing capabilities. This transaction is expected to reshape Abbott’s diagnostics offering and may be material for the company’s long term business mix. Abbott shares most recently closed at $107.19, with the stock showing a 17.2% return over 3 years and a...
XTRA:PCZ
XTRA:PCZBanks

ProCredit Holding (XTRA:PCZ) Margin Decline Tests Bullish Growth And Valuation Narratives

ProCredit Holding (XTRA:PCZ) has reported full year 2025 results with fourth quarter revenue of €121.2 million and EPS of €0.43, while trailing 12 month revenue came in at €428.1 million and EPS at €1.42 compared with €451.1 million of revenue and EPS of €1.77 a year earlier. Over the last two reported fourth quarters, revenue moved from €124.6 million in Q4 2024 to €121.2 million in Q4 2025, and EPS went from €0.33 to €0.43, setting up an earnings picture where investors will be focused on...
NasdaqGS:VIAV
NasdaqGS:VIAVCommunications

Viavi Steps Into NetSecOps Forensics With Observer And RSA Push

Viavi Solutions (NasdaqGS:VIAV) introduced Observer Threat Forensics, a cybersecurity and network analysis tool focused on NetSecOps convergence. The company plans to showcase Observer Threat Forensics at the RSA Conference, highlighting unified security and network visibility capabilities. For investors tracking Viavi Solutions, the move into threat forensics adds a new angle to a business already known for network test, monitoring, and visibility tools. Observer Threat Forensics shifts...
NasdaqGS:MKTX
NasdaqGS:MKTXCapital Markets

A Look At MarketAxess Holdings (MKTX) Valuation Following Recent Share Price Softness

MarketAxess Holdings (MKTX) runs an electronic bond trading platform, giving institutional investors and dealers access to liquidity across corporate and government fixed income markets. The company reports annual revenue of about US$846.3m and net income of US$246.6m. See our latest analysis for MarketAxess Holdings. The share price has softened recently, with a 7 day share price return of 3.76% and a 1 month share price return of 1.74%. However, the 1 year total shareholder return of 18.5%...
NasdaqGM:CRSP
NasdaqGM:CRSPBiotechs

Assessing CRISPR Therapeutics (CRSP) Valuation After CASGEVY Traction And US$600m Convertible Notes Raise

CRISPR Therapeutics (CRSP) has moved back into focus after reporting strong commercial traction for its approved gene therapy CASGEVY, along with the completion of a US$600 million convertible note offering that lifts pro forma cash above US$2.5b. See our latest analysis for CRISPR Therapeutics. Despite recent news on CASGEVY and the new convertible notes, the share price has cooled, with a 30-day share price return of an 11.74% decline and a 1-year total shareholder return of 13.99%,...
NasdaqGS:SVRA
NasdaqGS:SVRABiotechs

Will Advancing MOLBREEVI and a New HQ Lease Change Savara's (SVRA) Narrative?

Savara Inc. recently reported a US$32.24 million net loss for the fourth quarter of 2025, while also signing a new six-year headquarters lease in Yardley, Pennsylvania starting July 2026 with aggregate base rent of about US$1.78 million and five months of rent abatement. At the same time, the company advanced its lead therapy MOLBREEVI for autoimmune PAP, with the FDA confirming no advisory committee is planned and marketing applications progressing in Europe and the U.K., underscoring how a...
ASX:WAF
ASX:WAFMetals and Mining

A Look At West African Resources (ASX:WAF) Valuation After Strong 2025 Earnings And Kiaka Ramp Up

West African Resources (ASX:WAF) has caught investor attention after reporting strong 2025 earnings, supported by higher gold sales, the ramp up of the Kiaka production centre, and solid output from Sanbrado. See our latest analysis for West African Resources. Despite a softer patch recently, with a 30 day share price return of 19.94% decline and a year to date share price return of 5.86% decline from A$2.89, the 1 year total shareholder return of 25.65% and 3 year total shareholder return of...
TSX:ACQ
TSX:ACQSpecialty Retail

AutoCanada (TSX:ACQ) Margin Squeeze And Weak Interest Cover Test Bullish Growth Story

AutoCanada (TSX:ACQ) closed out FY 2025 with Q4 revenue of CA$1.1b and a basic EPS loss of CA$0.06. Trailing twelve month figures show revenue of CA$4.9b and basic EPS of CA$0.93, reflecting the swing between individual quarter losses and full year profitability. Over recent quarters, revenue has moved from CA$1.4b in Q3 2024 to CA$1.3b in Q2 2025 and CA$1.2b in Q3 2025 before landing at CA$1.1b in Q4 2025. Quarterly EPS has ranged from a loss of CA$0.15 in Q3 2025 to a gain of CA$0.75 in Q2...
NYSE:KTB
NYSE:KTBLuxury

Lee And J Crew Tie Up Tests Kontoor Brands Premium Potential

Kontoor Brands' Lee, part of NYSE:KTB, has launched an exclusive collaboration with J.Crew. The collection reimagines Lee's legacy denim styles with a fresh take on American classics. The capsule uses premium materials and is available for men, women, and kids through Lee.com and J.Crew. This is the first Lee collaboration spanning all age groups on Lee.com, signaling a shift toward a more premium, fashion forward positioning. Kontoor Brands, the owner of Lee and Wrangler, operates in a...
TSXV:LGN
TSXV:LGNOil and Gas

Logan Energy (TSXV:LGN) Net Margin Surge Challenges Bearish DCF Concerns

Logan Energy (TSXV:LGN) FY 2025 earnings snapshot Logan Energy (TSXV:LGN) has just wrapped up FY 2025 with Q4 total revenue of $45.1 million and basic EPS of $0.016, capping a trailing twelve month run of $163.7 million in revenue and EPS of $0.06 that sits alongside very large year on year earnings growth and a net profit margin of 23.1% versus 4.4% in the prior year. Over that same twelve month window, net income excluding extra items has moved from $4.6 million to $37.8 million, with...
NasdaqCM:LIND
NasdaqCM:LINDHospitality

How Lindblad’s Strong Revenue But Weak EPS At Lindblad Expeditions Holdings (LIND) Has Changed Its Investment Story

Earlier this week, Lindblad Expeditions reported a 23.3% year-on-year revenue increase and a strong EBITDA beat, but significantly missed analysts’ earnings-per-share estimates. This combination of robust top-line growth and weaker bottom-line performance has raised questions about how effectively the company is converting demand into sustainable profits. Next, we’ll explore how Lindblad’s strong revenue beat but weaker earnings performance could influence its investment narrative and future...